- call +1-201-465-4211
- email sales@mrinsights.biz
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Scope of the Report:
This report studies the Gene Therapy for Ovarian Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy for Ovarian Cancer market by product type and applications/end industries.
Gene therapy is expected to be one of the next big paradigm shift in pharmacology due to the extensive on-going research studies, both at academic and industry level. Gene therapy is one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy is gaining attention as it has the potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
The global Gene Therapy for Ovarian Cancer market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy for Ovarian Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Takara Bio
VBL Therapeutics
CELSION
Targovax
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Intravenous
Intratumoral
Intraperitoneal
Market Segment by Applications, can be divided into
Ovarian Cancer (unspecified)
Recurrent Ovarian Epithelial Cancer
Platinum-Resistant Ovarian Cancer
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Gene Therapy for Ovarian Cancer Market Overview
1.1 Product Overview and Scope of Gene Therapy for Ovarian Cancer
1.2 Classification of Gene Therapy for Ovarian Cancer by Types
1.2.1 Global Gene Therapy for Ovarian Cancer Revenue Comparison by Types (2017-2023)
1.2.2 Global Gene Therapy for Ovarian Cancer Revenue Market Share by Types in 2017
1.2.3 Intravenous
1.2.4 Intratumoral
1.2.5 Intraperitoneal
1.3 Global Gene Therapy for Ovarian Cancer Market by Application
1.3.1 Global Gene Therapy for Ovarian Cancer Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Ovarian Cancer (unspecified)
1.3.3 Recurrent Ovarian Epithelial Cancer
1.3.4 Platinum-Resistant Ovarian Cancer
1.4 Global Gene Therapy for Ovarian Cancer Market by Regions
1.4.1 Global Gene Therapy for Ovarian Cancer Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Gene Therapy for Ovarian Cancer Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy for Ovarian Cancer Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy for Ovarian Cancer Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy for Ovarian Cancer Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy for Ovarian Cancer Status and Prospect (2013-2023)
1.5 Global Market Size of Gene Therapy for Ovarian Cancer (2013-2023)
2 Manufacturers Profiles
2.1 Takara Bio
2.1.1 Business Overview
2.1.2 Gene Therapy for Ovarian Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Takara Bio Gene Therapy for Ovarian Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.2 VBL Therapeutics
2.2.1 Business Overview
2.2.2 Gene Therapy for Ovarian Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 VBL Therapeutics Gene Therapy for Ovarian Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.3 CELSION
2.3.1 Business Overview
2.3.2 Gene Therapy for Ovarian Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 CELSION Gene Therapy for Ovarian Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.4 Targovax
2.4.1 Business Overview
2.4.2 Gene Therapy for Ovarian Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Targovax Gene Therapy for Ovarian Cancer Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gene Therapy for Ovarian Cancer Market Competition, by Players
3.1 Global Gene Therapy for Ovarian Cancer Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Gene Therapy for Ovarian Cancer Players Market Share
3.2.2 Top 10 Gene Therapy for Ovarian Cancer Players Market Share
3.3 Market Competition Trend
4 Global Gene Therapy for Ovarian Cancer Market Size by Regions
4.1 Global Gene Therapy for Ovarian Cancer Revenue and Market Share by Regions
4.2 North America Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
4.3 Europe Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
4.5 South America Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
5 North America Gene Therapy for Ovarian Cancer Revenue by Countries
5.1 North America Gene Therapy for Ovarian Cancer Revenue by Countries (2013-2018)
5.2 USA Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
5.3 Canada Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
5.4 Mexico Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
6 Europe Gene Therapy for Ovarian Cancer Revenue by Countries
6.1 Europe Gene Therapy for Ovarian Cancer Revenue by Countries (2013-2018)
6.2 Germany Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
6.3 UK Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
6.4 France Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
6.5 Russia Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
6.6 Italy Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Gene Therapy for Ovarian Cancer Revenue by Countries
7.1 Asia-Pacific Gene Therapy for Ovarian Cancer Revenue by Countries (2013-2018)
7.2 China Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
7.3 Japan Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
7.4 Korea Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
7.5 India Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
8 South America Gene Therapy for Ovarian Cancer Revenue by Countries
8.1 South America Gene Therapy for Ovarian Cancer Revenue by Countries (2013-2018)
8.2 Brazil Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
8.3 Argentina Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
8.4 Colombia Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Gene Therapy for Ovarian Cancer by Countries
9.1 Middle East and Africa Gene Therapy for Ovarian Cancer Revenue by Countries (2013-2018)
9.2 Saudi Arabia Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
9.3 UAE Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
9.4 Egypt Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
9.5 Nigeria Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
9.6 South Africa Gene Therapy for Ovarian Cancer Revenue and Growth Rate (2013-2018)
10 Global Gene Therapy for Ovarian Cancer Market Segment by Type
10.1 Global Gene Therapy for Ovarian Cancer Revenue and Market Share by Type (2013-2018)
10.2 Global Gene Therapy for Ovarian Cancer Market Forecast by Type (2018-2023)
10.3 Intravenous Revenue Growth Rate (2013-2023)
10.4 Intratumoral Revenue Growth Rate (2013-2023)
10.5 Intraperitoneal Revenue Growth Rate (2013-2023)
11 Global Gene Therapy for Ovarian Cancer Market Segment by Application
11.1 Global Gene Therapy for Ovarian Cancer Revenue Market Share by Application (2013-2018)
11.2 Gene Therapy for Ovarian Cancer Market Forecast by Application (2018-2023)
11.3 Ovarian Cancer (unspecified) Revenue Growth (2013-2018)
11.4 Recurrent Ovarian Epithelial Cancer Revenue Growth (2013-2018)
11.5 Platinum-Resistant Ovarian Cancer Revenue Growth (2013-2018)
12 Global Gene Therapy for Ovarian Cancer Market Size Forecast (2018-2023)
12.1 Global Gene Therapy for Ovarian Cancer Market Size Forecast (2018-2023)
12.2 Global Gene Therapy for Ovarian Cancer Market Forecast by Regions (2018-2023)
12.3 North America Gene Therapy for Ovarian Cancer Revenue Market Forecast (2018-2023)
12.4 Europe Gene Therapy for Ovarian Cancer Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gene Therapy for Ovarian Cancer Revenue Market Forecast (2018-2023)
12.6 South America Gene Therapy for Ovarian Cancer Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gene Therapy for Ovarian Cancer Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Gene Therapy for Ovarian Cancer Picture
Table Product Specifications of Gene Therapy for Ovarian Cancer
Table Global Gene Therapy for Ovarian Cancer and Revenue (Mil
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
